A part of MilliporeSigma

36-008 | Anti-α-Synuclein Antibody, clone Syn211

200 µL  
Retrieving price...
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
Request Pricing
Limited AvailabilityLimited Availability
Limited Quantities Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service

      Special Offers


      Contact Customer Service

      Click To Print This Page


      Replacement Information

      Key Specifications Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      H IP, WB, IHC M Ascites Monoclonal Antibody
      Catalogue Number36-008
      Brand Family Upstate
      Trade Name
      • Upstate
      DescriptionAnti-α-Synuclein Antibody, clone Syn211
      Product Information
      Presentationascites with 0.05% sodium azide
      ApplicationDetect α-Synuclein using this Anti-α-Synuclein Antibody, clone Syn211 validated for use in IP, WB, IH.
      Key Applications
      • Immunoprecipitation
      • Western Blotting
      • Immunohistochemistry
      Biological Information
      Immunogenfull-length recombinant human α-Synuclein
      Cloneclone Syn211
      Species Reactivity
      • Human
      Antibody TypeMonoclonal Antibody
      Entrez Gene Number
      Entrez Gene SummaryAlpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Two alternatively spliced transcripts of SNCA have been identified. Additional splicing may be present but the full-length nature of these variants has not been determined.
      Gene Symbol
      • SNCA
      • MGC110988
      • PD1
      • alpha-synuclein
      • NACP
      • PARK1
      • PARK4
      • Alpha-synuclein
      Purification MethodAscites
      UniProt Number
      UniProt SummaryFUNCTION: SwissProt: P37840 # May be involved in the regulation of dopamine release and transport. Soluble protein, normally localized primarily at the presynaptic region of axons, which can form filamentous aggregates that are the major non amyloid component of intracellular inclusions in several neurodegenerative diseases (synucleinopathies). Induces fibrillization of microtubule- associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase 3 activation.
      SIZE: 140 amino acids; 14460 Da
      SUBUNIT: Soluble monomer which can form filamentous aggregates. Interacts with UCHL1 (By similarity). Interacts with phospholipase D and histones.
      SUBCELLULAR LOCATION: Cytoplasm. Membrane. Nucleus. Note=Membrane- bound in dopaminergic neurons. Also found in the nucleus.
      TISSUE SPECIFICITY: Expressed principally in brain but is also expressed in low concentrations in all tissues examined except in liver. Concentrated in presynaptic nerve terminals.
      DOMAIN: SwissProt: P37840 The NAC domain is involved in the fibril formation. The middle region forms the core of the filaments. The C-terminus may regulate aggregation and determine the diameter of the filaments.
      PTM: Phosphorylated, predominantly on serine residues. Phosphorylation by CK1 appears to occur on residues distinct from the residue phosphorylated by other kinases. Phosphorylation of Ser-129 is selective and extensive in synucleinopathy lesions. In vitro, phosphorylation at Ser-129 promoted insoluble fibril formation. Phosphorylated on Tyr-125 by a PTK2B-dependent pathway upon osmotic stress. & Hallmark lesions of neurodegenerative synucleinopathies contain alpha-synuclein that is modified by nitration of tyrosine residues and possibly by dityrosine cross-linking to generated stable oligomers. & Ubiquitinated. The predominant conjugate is the diubiquitinated form (By similarity).
      DISEASE: SwissProt: P37840 # Defects in SNCA are a cause of autosomal dominant Parkinson disease 1 (PARK1) [MIM:168601, 168600]. Parkinson disease (PD) is a complex, multifactorial disorder that typically manifests after the age of 50 years, although early-onset cases (before 50 years) are known. PD generally arises as a sporadic condition but is occasionally inherited as a simple mendelian trait. Although sporadic and familial PD are very similar, inherited forms of the disease usually begin at earlier ages and are associated with atypical clinical features. PD is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. & Defects in SNCA are the cause of Parkinson disease 4 (PARK4) [MIM:605543, 168600]. & Defects in SNCA are the cause of Lewy body dementia (DLB) [MIM:127750]. DLB is a neurodegenerative disorder clinically characterized by dementia and parkinsonism, often with fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Presence of Lewy bodies are the only essential pathologic features. & Deposition of fibrillar amyloid proteins intraneuronally as neurofibrillary tangles is characteristic of Alzheimer disease (AD). SNCA is a minor protein found within these deposits, but a major non amyloid component. & Brain iron accumulation type 1 (NBIA1, also called Hallervorden-Spatz syndrome), a rare neuroaxonal dystrophy, is histologically characterized by axonal spheroids, iron deposition, Lewy body (LB)-like intraneuronal inclusions, glial inclusions and neurofibrillary tangles. SNCA is found in LB-like inclusions, glial inclusions and spheroids.
      SIMILARITY: Belongs to the synuclein family.
      Molecular Weight~14.5kDa
      Physicochemical Information
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality AssuranceRoutinely evaluated by immunoblot on Alzheimers diseased human whole brain lysates.
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage Conditions2 years at -20°C
      Packaging Information
      Material Size200 µL
      Transport Information
      Supplemental Information




      Safety Data Sheet (SDS) 

      Certificates of Analysis

      TitleLot Number
      Anti-#945;-Synuclein, clone Syn211 (mouse ascites) - 2115569 2115569
      Anti-#945;-Synuclein, clone Syn211 (mouse ascites) - 2127808 2127808
      Anti-#945;-Synuclein, clone Syn211 - DAM1770356 DAM1770356
      Anti-a-Synuclein, clone Syn211 (mouse ascites) - 2109536 2109536
      Anti-a-Synuclein, clone Syn211 (mouse ascites) - 2227152 2227152
      Anti-a-Synuclein, clone Syn211 (mouse ascites) - 2295475 2295475
      Anti-a-Synuclein, clone Syn211 - 2041584 2041584
      Anti-a-Synuclein, clone Syn211 - 2058949 2058949
      Anti-a-Synuclein, clone Syn211 - DAM1824771 DAM1824771
      Anti-a-Synuclein, clone Syn211 - JBC1870031 JBC1870031
      Anti-a-Synuclein, clone Syn211 - NG1896097 NG1896097
      Anti-a-Synuclein, clone Syn211 - NG1942982 NG1942982
      Anti-alpha;-Synuclein, clone Syn211 - 26778 26778
      Anti-α-Synuclein, clone Syn211 (mouse ascites) - 2394018 2394018
      Anti-α-Synuclein, clone Syn211 -2504870 2504870
      Anti-α-Synuclein, clone Syn211 -2642581 2642581
      Anti-α-Synuclein, clone Syn211 -2700898 2700898
      Anti-α-Synuclein, clone Syn211 -2717649 2717649
      Anti-α-Synuclein, clone Syn211 -2736465 2736465
      Anti-α-Synuclein, clone Syn211 -2762298 2762298
      Anti--Synuclein, clone Syn211 -2814781 2814781


      Reference overviewApplicationPub Med ID
      Neuron-to-neuron α-synuclein propagation in vivo is independent of neuronal injury.
      Ulusoy, A; Musgrove, RE; Rusconi, R; Klinkenberg, M; Helwig, M; Schneider, A; Di Monte, DA
      Acta neuropathologica communications 3 13 2015

      Show Abstract
      25853980 25853980
      Caudo-rostral brain spreading of α-synuclein through vagal connections.
      Ulusoy, A; Rusconi, R; Pérez-Revuelta, BI; Musgrove, RE; Helwig, M; Winzen-Reichert, B; Di Monte, DA
      EMBO molecular medicine 5 1051-9 2013

      Show Abstract
      Immunohistochemistry23703938 23703938
      Characterization of cognitive deficits in rats overexpressing human alpha-synuclein in the ventral tegmental area and medial septum using recombinant adeno-associated viral vectors.
      Hall, H; Jewett, M; Landeck, N; Nilsson, N; Schagerlöf, U; Leanza, G; Kirik, D
      PloS one 8 e64844 2013

      Show Abstract
      Immunohistochemistry23705016 23705016
      Oxidative stress and nitration in neurodegeneration: cause, effect, or association?
      Ischiropoulos, Harry and Beckman, Joseph S
      J. Clin. Invest., 111: 163-9 (2003) 2003

      12531868 12531868
      Alpha-synuclein: its biological function and role in neurodegenerative diseases.
      Kaplan, Batia, et al.
      J. Mol. Neurosci., 20: 83-92 (2003) 2003

      Show Abstract
      12794302 12794302
      Oxidative modifications of alpha-synuclein.
      Ischiropoulos, Harry
      Ann. N. Y. Acad. Sci., 991: 93-100 (2003) 2003

      Show Abstract
      12846977 12846977
      Development of new treatments for Parkinson's disease in transgenic animal models: a role for beta-synuclein.
      Masliah, Eliezer and Hashimoto, Makoto
      Neurotoxicology, 23: 461-8 (2002) 2002

      Show Abstract
      12428718 12428718
      A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease
      Giasson, B. I., et al
      J Neurosci Res, 59:528-33 (2000) 2000

      Immunoblotting (Western), Immunohistochemistry (Tissue)10679792 10679792

      Related Products & Applications

      Related Products

      Catalog Number Description  
      04-1050 Anti-γ-Synuclein Antibody, clone EP1539Y, rabbit monoclonal Show Pricing & Availability
      04-1053 Anti-α-Synuclein (NT) Antibody, clone EP1646Y, rabbit monoclonal Show Pricing & Availability
      36-008-C Anti-alpha-Synuclein (aa 121-125) Antibody, clone Syn211 (Ascites Free) Show Pricing & Availability
      AB5038 Anti-Synuclein α Antibody Show Pricing & Availability
      AB5038P Anti-Synuclein α Antibody Show Pricing & Availability
      AB5334P Anti-Synuclein α Antibody Show Pricing & Availability
      AB5336P Anti-Synuclein α Antibody Show Pricing & Availability
      AB9850 Anti-phospho-α Synuclein (Ser129) Antibody Show Pricing & Availability
      MAB5320 Anti-Synuclein α Antibody, clone 7B12.2 Show Pricing & Availability
      MABN389 Anti-Aggregated a-Synuclein Antibody, clone 5G4 Show Pricing & Availability
      MABN633 Anti-a-Synuclein, clone 10D2 Antibody Show Pricing & Availability
      MABN824 Anti-α-syn Antibody (amino acids 115-122), clone LB509 Show Pricing & Availability
      MABN826 Anti-phospho-α-Synuclein (Ser129) Antibody, clone 81A Show Pricing & Availability


      Life Science Research > Antibodies and Assays > Primary Antibodies